Back to Search
Start Over
A phase II study of mitoxantrone in advanced gastric cancer
A phase II study of mitoxantrone in advanced gastric cancer
- Source :
- Investigational new drugs. 8(3)
- Publication Year :
- 1990
-
Abstract
- Sixteen patients with advanced adenocarcinoma of the stomach were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. Nine patients had received prior chemotherapy including doxorubicin. No patients achieved either a complete or partial response, five patients had stable disease and the remainder disease progression. Moderate to severe leukopenia occurred in 10 patients with one septic death. Median survival for all patients was eight weeks (range 1–49 weeks). It is concluded that mitoxantrone has no worthwhile activity in gastric cancer at the described doses.
- Subjects :
- Adult
medicine.medical_specialty
medicine.medical_treatment
Phases of clinical research
Adenocarcinoma
Gastroenterology
Stomach Neoplasms
Internal medicine
medicine
Humans
Pharmacology (medical)
Doxorubicin
Aged
Pharmacology
Aged, 80 and over
Mitoxantrone
Chemotherapy
Leukopenia
business.industry
Stomach
Cancer
Middle Aged
medicine.disease
Surgery
medicine.anatomical_structure
Oncology
Drug Evaluation
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 01676997
- Volume :
- 8
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Investigational new drugs
- Accession number :
- edsair.doi.dedup.....8e0a121b80ab7629dcd1da3cbf64209e